Season of initial discovery of tumour as an independent variable predicting survival in breast cancer. by Mason, B. H. et al.
Br. J. Cancer (1990), 61, 137 141
Season of initial discovery of tumour as an independent variable
predicting survival in breast cancer
B.H. Mason', I.M. Holdaway2, A.W. Stewart3, L.M. Neave4 & R.G. Kay4
Departments of'Surgery and 2Endocrinology, Auckland Hospital and Departments of3Community Health and4Surgery, University
ofAuckland, Auckland, New Zealand.
Summary The month of initial detection of tumour was recorded in 2,245 patients with breast cancer and
correlated with survival over a follow-up period of 1.5-10 years. Women who initially detected their breast
cancer in spring/summer had a significantly longer survival than those detecting their tumour at other times of
the year. Overall, this relationship was independent of nodal status, tumour size and hormone receptor status.
However, when patients were divided into groups the survival advantage was significantly associated with
receptor status and age. Women aged > 50 years with ER-positive and PR-positive tumours who discovered
their initial tumour in spring/summer had significantly better survival than those detecting their tumours at
other times of the year. Survival was also longer in women aged < 50 years with receptor-negative tumours
who initially found their tumours in spring/summer compared with the rest of the year. This study suggests
that the season of first detection of a breast cancer relates significantly to the later behaviour of the tumour,
and may reflect seasonal changes in hormone dependent growth.
A circannual rhythm of detection of breast cancer has been
described by a number of workers in different countries, with
a significantly increased frequency of tumour detection in
spring/summer (Lee, 1967; Jacobsen & Janerich, 1977; Cohen
et al., 1983; Hartveit et al., 1983; Mason et al., 1985; Kirk-
ham et al., 1985). This seasonal trend occurs predominantly
in young or premenopausal women (Lee, 1967; Cohen et al.,
1983; Mason et al., 1985; Kirkham et al., 1985), and has been
correlated with the presence of tumour hormone receptors
(Jacobsen et al., 1977; Mason et al., 1985).
Premenopausal women with breast cancer who find their
tumours in the summer have a disease-free interval which is
significantly longer than seen in patients who find their
tumour in the winter (Mason et al., 1987). In a preliminary
report (Cohen, 1983), women who detect their tumours in
spring and summer have been shown to have better survival
than those who detect their tumours in winter and autumn.
In the present study the relationship between season of
tumour detection and overall survival has been assessed both
overall and in patient subgroups divided according to age
and tumour receptor status.
Methods
The Auckland Breast Cancer Study Group commenced
recording clinical data on all new breast cancer cases in
Auckland (1981 population 829,000) detected between 1976
and 1985, with a total of 2,706 cases. Follow-up has been
1.5-10.5 years, with survival taken from the month when the
cancer. was first detected by the patient. Of the 2,706 cases
the month of first detection of tumour was recorded in 2,245.
Three per cent have been lost to follow-up. Of the 2,245
cases axillary nodes were removed and examined his-
tologically in 1,685 and oestrogen and progesterone receptor
results were available in 1,132 patients. Both nodal and
tumour receptor status was known for 976 cases. When
estimating survival, death was recorded as due to breast
cancer if directly caused by breast cancer or if metastatic
disease was known to be present at the time of death. All
deaths from other causes were recorded as day ofdeath being
equivalent to last follow-up date and this applies to 5% of
the patients. Follow-up records of patients are updated by
means of a computer generated form which is sent to the
patient's family practitioner every 9 months. It is inserted
into the patient notes until her next consultation. Other
sources are contacted for information regarding the patient
in all cases where it is more than 1 year since the last
follow-up date. All censored data have the date of last
contact as the date of censoring.
The assay methods for steroid hormone receptor
measurements have been recorded elsewhere (Holdaway,
1982). Due to changes in assay methodology a positive value
for progesterone receptors (PR) was changed in 1980 from
) 3 to >5 fmol mg-' of protein. Oestrogen receptor (ER)
values were defined as positive when 5 fmol mg-' (Hold-
away, 1982).
There was no seasonal difference in the proportion of
patients who received adjuvant therapy. Patients were divided
by age at 50 years and also according to axillary nodal
status. Receptor subgroups were analysed according to the
following groupings: ER positive PR positive; ER positive
PR negative; ER negative PR positive; and ER negative PR
negative.
Statistical methods
The relationship between survival and month of initial
tumour detection was assessed in two ways. Initially
'periodic' terms were used in a proportional hazards regres-
sion to model the survival during the months of the year. To
do this the hazard function was modelled using the following
expression (Armitage et al., 1987):
T(t,x) = T0(t)exp(3x)
where Px represents the regression function, l,x, + P2x2 +
* + &x, and To(t) is the time dependent part of the hazard.
The x, and x2 terms were defined to be the periodic func-
tions, cos (rt m/6) and sin (rcm/6) respectively, where m is
month of year 1- 12. In this way the significance of any
periodic effect was determined together with the month of
tumour detection associated with maximum survival. In addi-
tion survival was compared with season of tumour detection
by dividing the year into categories of season according to
Mason et al. (1985). In this method the period of peak
tumour detection (October to January, defined as 'spring/
summer') was compared with the remainder of the year and
this comparison was performed using four other prognostic
variables (nodal status, tumour size, ER status and PR
status). The effect of season on survival, adjusting for the
other prognostic variables, was then determined by compar-
ing maximised log likelihoods with and without season
included in the proportional hazards regression model. The
difference in these values is distributed approximately as X2,
with the difference in the number of parameters being the
degrees of freedom. This method was repeated in ER, PR,
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axillary node and age subgroups with the effect of season
being adjusted for axillary nodal status. The odds ratio
relating season to survival is estimated by eb (where b is the
estimator of P from the above proportional hazards regres-
sion model), and the confidence interval using the test base
method (Miettinen, 1976), (eb)( +± .961x) where X is the square
root of X2.
Results
When the month of initial tumour detection was related to
survival using the sinusoidal 'periodic' method a significant
variation in survival was observed between months with
detection in December being associated with longest survival
(x2 = 7.42, d.f. = 2, P = 0.02). This is consistent with
previous data where, calculating monthly detection rates of
breast cancer using a two month moving average, the 4-
month interval October to January was found to be the peak
period for tumour detection (Mason et al., 1985). Survival in
patients detecting their tumours in October to January was
thus compared with the remaining 8 months of the year and
a significantly longer survival was found for those who
detected their tumours during October to January, (X2 = 7.59,
d.f. = 1, P = 0.006, odds ratio = 1.25, confidence inter-
val= 1.07-1.47; Figure 1). In patient subgroups divided by
receptor status, nodal status or age and analysed by the
sinusoidal period method there was no significant variation
in survival over the year. Therefore survival according to
tumour detection in October to January versus February to
September was studied in more detail.
The survival advantage for those detecting their tumour in
October to January was independent of nodal status, tumour
size, oestrogen receptor status or progesterone receptor
status when adjustment was made for each variable using the
Cox's proportional hazards model. When all these variables
were adjusted for, survival was still significantly related to
season of initial tumour detection (P = 0.06; Table I).
Separation of groups by tumour receptor status showed a
significant survival advantage for patients first detecting
tumours in spring/summer compared with the remainder of
the year in those with either ER positive or ER positive PR
positive tumours. Overall no such survival difference was
apparent for those with receptor negative tumours. However,
these findings varied according to patient age. Women aged
> 50 years with ER positive tumours had 13% improvement
in survival at 5 years if the initial tumour was detected in
spring/summer (X2 = 12.87, P = 0.0003, odds ratio = 2.04,
confidence interval= 1.38-3.01; Figure 2). In premenopausal
women with receptor positive tumours there was no
significant relationship between season of detection and sur-
vival. However, in contrast to post-menopausal women,
premenopausal patients had improved survival (26% at 5
years) if they had receptor negative tumours which were
found initially in the spring/summer. The significance of this
finding was, however, borderline (X2 = 3.64, P = 0.06, odds
ratio = 2.3, confidence interval = 0.98-5.41; Figure 3). Sur-
vival of patients in different ER and PR subgroups is shown
in Table II according to season of initial tumour detection.
This analysis was restricted to those patients with known
nodal status, and adjustment for nodal involvement did not
alter the effect of season of tumour detection on survival.
The results are similar to the overall group. Thus the most
significant survival advantage, 14% at 5 years, was seen in
100
90
80
cm 70
60
2 50
Cn
x 40
30
20-
10
0-
.----.
0 1 2 3 4 5 6
Years
7 8
Figure 1 Survival of patients with breast cancer according to
season of detection of tumour. , October to January,
n = 825, died = 210; February to September, n = 1420,
died=419; x2=7.59, d.f.=1, P=0.006.
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Figure 2 Survival of patients with breast cancer according to
season of detection of tumour for women > 50 years with oes-
trogen receptor positive tumours. , October to January,
n = 228, died = 32; February to September, n = 394,
died = 90; x2= 12.87, d.f. = 1, P = 0.0003.
Table I The relationship between survival ofpatients with breast cancer and season oftumourdetection, nodal status, tumoursize and
tumour receptor status (n = 976)
x2 based on 95%
maximised log Odds confidence
Variable likelihood d.f. P ratio interval
Axillary nodes 66.96 1 0.0001 3.14 2.39, 4.13
Tumour size 27.73 1 0.0001 2.3 1.69, 3.14
Oestrogen receptor (ER) 13.58 1 0.0002 0.59 0.78, 0.46
Progesterone receptor (PR) 13.11 1 0.0003 0.6 0.79, 0.46
Season of tumour detection 4.70 1 0.03 1.37 1.03, 1.82
Effect ofseason x2
adjustedfor difference d.f. P
Season and nodes 71.70 2 nodes 4.74 1 0.03
Season and tumour size 32.08 2 size 4.35 1 0.04
Season and ER 17.39 2 ER 3.81 1 0.05
Season and PR 17.94 2 PR 4.83 1 0.03
Nodes, tumour size 80.76 2
Nodes, tumour size, ER 93.94 3
Nodes, tumour size, ER, PR 99.56 4
Nodes, tumour size, ER, PR, season 102.89 5 nodes, size,
ER, PR 3.33 1 0.06
Data were analysed by Cox's life table regression analysis.
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Figure 3 Survival of patients with breast cancer according to
season of detection of tumour for women < 50 years with oes-
trogen and progesterone receptor negative tumours.
October to January, n = 34, died =6;.February to September,
n =52, died =20; X'=3.4 d.f. 1, P =0.06.
older patients with ER positive PR positive tumours initially
detected in spring/summer (X2
= 10.43, P = 0.00 1, odds
ratio = 3.51, confidence interval = 1.64-7.52). However a
survival advantage of 29% at 5 years was also seen in
younger patients with ER negative PR negative tumours
initially detected in spring/summer (X2 = 3.96, P = 0.05, odds
ratio = 2.77, confidence interval = 1.02-7.56). In confirma-
tion of the results of Table II an interaction was shown
between season and oestrogen receptor values which in com-
bination are significantly related to survival after adjusting
for the effect of progesterone receptor status.
In other subgroup analyses, there was improved survival in
node positive patients who detected their tumours in spring/
summer (X2
= 4.54, P = 0.03, odds ratio = 1.33, confidence
interval = 1.02-1.73; Figure 4 and Table II) but not in node
negative patients. When survival was studied in groups
divided according to age < or >, 50 years, the results varied
according to whether all patients or only those with known
nodal status were used in the analysis. For all patients aged
< 50 years there was a significant survival advantage (12%
at 5 years) for those who found their tumour in the spring/
summer (X2
= 4.45, P = 0.03, odds ratio = 1.4, confidence
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Figure 4 Survival of patients with breast cancer according to
season of detection of tumour and axillary nodal status. node
negative 4: ~, months Oct. to Jan., n = 372, died = 53;
Feb. to Sep., n= 630, died = 92; X2
= 1.02, d.f. = 1, P= 0.3.
Node positive 4: - , months Oct. to Jan., n= 248, died= 77;
...IFeb. to Sep., n =435, died =171; X2=4.54, d.f.=1,
P =0.03.
initerval
= 1.02-1.91). For women aged >,50 years there
was also a survival advantage (5% at 5 years) for those
detecting their tumours in the spring/summer (X2
= 3.66,
P = 0.06, odds ratio = 1.2, confidence interval = 1.00-1.45).
However, when nodal status was known there was no longer
a significant survival difference for women <50 years
(X2= 1.23, P = 0.26, odds ratio = 1.23, confidence inter-
val 0.85-1.77) whereas the survival difference increased to
7% at 5 years for women > 50 years (X2 = 5.02, P = 0.02,
odds ratio = 1.33, confidence interval = 1.04-1.71; Table II).
The analyses shown in Tables I and II were restricted to
the subgroup of patients with known nodal and receptor
status. Of the original 2,245 patients, 25% (560 patients) had
an unknown nodal status. Although in this group there was a
trend towards longer survival for those whose tumours were
detected in spring/summer, the difference in survival between
the seasons was not significant (X2
= 1.61, P = 0.20, odds
ratio =1.18, confidence interval =0.91- 1.53). This group
had a greater proportion of patients with large tumours
Table II The relationship between survival of patients with breast cancer and season of tumour detection in various patient
subgroups
x2 based on 95%
maximised log Odds confidence
Patient subgroup Age Variable n likelihood df. P ratio interval
ER - ye PR - ye <50 season 74 3.96 1 0.05 2.77 1.02, 7.56
ER - ye PR + ye <50 season 52 2.06 1 0.15 0.38 1.42, 0.10
ER+vePR-ve <50 season 34 1
ER+vePR+ve <50 season 129 0.17 1 0.68 1.18 0.53,2.6
ER-vePR-ve >50 season 151 0.31 1 0.57 0.85 1.5, 0.48
ER-vePR+ve >50 season 56 1.37 1 0.24 0.52 1.56,0.17
ER+vePR-ve >50 season 161 2.67 1 0.10 1.73 0.89,3.34
ER+vePR+ve >50 season 319 10.43 1 0.001 3.51 1.64,7.52
axillary nodes + ye all season 683 4.54 1 0.03 1.33 1.02, 1.73
axillary nodes - ye all season 1002 1.02 1 0.31 1.18 0.86, 1.63
age <50 years season 511 1.23 1 0.26 1.23 0.85, 1.77
age >50 years season 1174 5.02 1 0.02 1.33 1.04, 1.71
Effect of
season x
adjustedfor difference df. P
ER - ye PR - ye <50 axillary
nodes 74 5.10 1 0.03
ER-vePR-ve <50 season
and nodes 74 8.75 2 nodes 3.65 1 0.06
ER + ye PR + ye >50 axillary
nodes 319 24.10 1 0.0001
ER + ye PR + ye season 319 33.23 2 nodes 9.13 1 0.003
and nodes
age> 50 years >50 axillary
nodes 1174 103.48 1 0.0001
age> 50 years season
and nodesll74 107.15 2 nodes 3.67 1 0.06
Analysis as for Table I. 'Insufficient deaths for reliable statistics.
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> 5 cm (47%) and patients with distant metastases at pres-
entation (22%) compared with the group with known nodal
status (11% and 6% respectively). In similar fashion the
combined ER and PR receptor status was unknown in 50%
(1,113 patients) of the original 2,245 patients, and in this
subgroup season of detection also did not significantly
predict length of survival (X2 = 2.05, P = 0.14, odds
ratio = 1.17, confidence interval = 0.94-1.45), compared with
1,132 patients of known ER and PR status (x2 = 7.00,
P = 0.008, odds ratio = 1.4, confidence interval = 1.09-1.80).
However, for women aged < 50 years there was a trend for
those who found their tumours in spring/summer to survive
longer (n = 297, x2 = 2.9, P = 0.08, odds ratio = 1.46,
confidence interval = 0.94-2.26). This is not so apparent for
older women (X2 = 0.53, P = 0.46, odds ratio = 1.09,
confidence interval = 0.86-1.37).
The characteristics of the patient subgroups of known or
unknown receptor or nodal status are shown in Table III.
Apart from significantly more large tumours in the group
with unknown nodal status there was no significant
differences in patient characteristics between these groups.
Division by age < and > 50 years did not alter these
findings.
In order to justify further the analysis of seasonal changes
by comparing survival in patients discovering their tumours in
October to January compared with the remainder of the year,
the survival of women aged >50 years with ER positive
tumours detecting their tumours in October to January was
compared with those with tumour detection from February
to May (decreasing light) and June to September (increasing
light). The odds ratios were 3.54 and 3.34 respectively, with
no apparent difference when comparing season of increasing
or decreasing light. The seasonal variations thus do not
appear to relate to photoperiod.
Discussion
This investigation suggests that the season of initial tumour
detection is a significant specific prognostic variable in
women with breast cancer. There is an overall survival
advantage for women who initially detect their tumour in
spring/early summer, and this effect is particularly pro-
nounced in various subgroups. Thus, patients aged >.50
years with ER positive tumours detected initially in spring/
summer had a significant survival advantage of 13% at 5
years compared with those detecting tumours at other times
of the year (Figure 2). In contrast, younger women aged
< 50 years detecting their tumours in spring/summer had a
survival advantage of 26% at 5 years if their tumours were
receptor negative (Figure 3). The effect of season of detection
appears to be a specific prognostic feature independent of
tumour nodal or receptor status (Table I). There was also a
survival difference of 10% at 5 years in axillary node positive
Table Ill Characteristics of patient subgroups by receptor or nodal
status
Nodal Nodal Receptors
status status Receptors not
known unknown measured measured
Variable (0) (0) (0) (%)
Age <50 years 30 19.5 28.5 27
Age >50 years 70 80.5 71.5 73
Size .5cm 11 47 16 24
Size < Scm 89 53 84 76
Adjuvant treatment 23 34 26 25.5
No adjuvant treatment 77 66 74 74.5
Tumour detection
months 10-1 37 37 35.5 38
months 2-9 63 63 64.5 62
Deaths
months 10-1 30 30 31 30
months2 -9 70 70 69 70
patients who detected their tumour in spring/summer. This
difference was, however, reduced to 4% and was no longer
significant in axillary node negative patients. This could
reflect the greater number of deaths in node positive com-
pared with node negative patients, and it may take a longer
time for significant differences to emerge in the latter group.
There appears to be a potential discrepancy between the
observation that all women aged < 50 years who detected
their tumours in spring/summer had a significantly improved
survival compared with those detecting their tumours over
the rest of the year, whereas no such advantage was seen for
the subgroup of women aged < 50 years who had a known
nodal status. However, 57% and 63% of women aged < 50
years with nodal status known were positive for ER and PR
respectively, whereas in the group with unknown nodal status
50% were ER positive and 47% were PR positive. The
influence of season of detection on survival in younger
women was confined to ER negative PR negative women
(Figure 3) and hence the comparative decrease in the propor-
tion of receptor negative patients in the nodal status known
group above may explain this discrepancy.
The survival advantage for women detecting their tumours
in spring/summer was not seen in the subgroup of patients
where receptor status was unknown. Even so, there were
clear trends in the survival of these groups in the same
direction as found in the overall group. Subgroup analysis
suggests that oestrogen receptor status has an important
influence on the interaction of survival and season of tumour
detection and it is possible that failure to show significant
results in the receptor unknown group could be due to an
unusual distribution of receptor status in these patients.
The cause of seasonal variation in the frequency of detec-
tion of breast cancer and the means by which this influences
patient survival remain uncertain. There is, however,
evidence to support an association between breast cancer,
tumour receptor status, melatonin production and/or pineal
function which could be implicated in seasonal changes in
tumour growth and detection. Thus, it has been shown that
pre- and post-menopausal women with ER positive and PR
positive tumours have a decreased nocturnal surge in plasma
melatonin (Danforth et al., 1982, 1985). Tryptophan is a
precursor of melatonin and urinary tryptophan metabolites
are lower in women with ER negative tumours or ER
positive PR negative tumours than in those with ER positive
PR positive cancers (Lehrer et al., 1986). Melatonin increases
ER concentrations in human breast cancer cells in vitro
(Danforth et al., 1983), and physiological levels of melatonin
inhibit the growth of ER positive cells in vitro (Hill, 1988).
Circannual changes in vitamin D and/or intracellular calcium
levels could also contribute to seasonal effects in women with
breast cancer.
The cause of the relationship between season of detection
and survival is uncertain. In premenopausal women, an in-
crease in oestrogen production in spring/summer (Kaupilla et
al., 1987) may induce a seasonal acceleration of tumour
growth leading to an increase in the rate of detection at this
time, particularly in women with receptor positive tumours.
Since these cancers are largely hormone-dependent, further
tumour growth remains under hormonal regulation and
overall survival is not significantly influenced by such
seasonal factors. In contrast, post-menopausal women have
no seasonal change in tumour growth and detection because
ovarian activity has ceased. However, in these women,
seasonal changes in other hormones such as increased
melatonin or decreased prolactin could lead to some inhibi-
tion of tumour growth and so improve overall survival. It is
more difficult to visualise how survival is influenced in young
women with receptor negative tumours.
Regardless of the explanation for those findings it appears
that season of detection of tumour is a hitherto unrecognised
prognostic variable in patients with breast cancer. It provides
information on prognosis additional to accepted indices such
as nodal and receptor status. The biological mechanism by
which season of detection relates to prognosis remains to be
determined. However, it appears important to record theSEASON OF DISCOVERY OF BREAST CANCER 141
month of first detection of tumour in individual patients
since this will obviously influence the analysis of results of
treatment.
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